ProCE Banner Activity

CE / CME

Precision Medicine Approaches in the Management of Cholangiocarcinoma

Text Module
Learn how multidisciplinary experts treat cholangiocarcinoma in this interactive text module with perspectives from Christine Chio, PharmD, BCOP; Lipika Goyal, MD; and Caroline Kuhlman, NP, on new agents and approaches and applying biomarkers in treatment strategies.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: May 13, 2022

Expiration: May 12, 2023

No longer available for credit.

Share

Faculty

Christine Chio

Christine Chio, PharmD, BCOP

Clinical Ambulatory GI Oncology Pharmacist
Department of Pharmacy
Massachusetts General Hospital
Boston, Massachusetts

Lipika Goyal

Lipika Goyal, MD, MPhil

Associate Professor in Medicine
Director of Gastrointestinal Oncology
Stanford School of Medicine
Palo Alto, California

Caroline Kuhlman

Caroline Kuhlman, NP

Nurse Practitioner
GI Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Incyte Corporation

Target Audience

This educational program is intended for physicians, pharmacists, nurses and other HCPs who treat patients with CCA.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate clinical data on the use of targeted therapy approaches for patients with CCA
  • Plan optimal, individualized therapy approaches for patients with disease progression following initial therapy
  • Order appropriate molecular profiling to identify patients suitable for targeted therapy
  • Select optimal treatment for patients with CCA based on molecular characterization of the tumor, previous treatment, and patient characteristics and preferences
  • Develop strategies to identify and mitigate unique AEs associated with targeted therapies in patients with CCA

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Christine Chio, PharmD, BCOP

Clinical Ambulatory GI Oncology Pharmacist
Department of Pharmacy
Massachusetts General Hospital
Boston, Massachusetts

Christine Chio, PharmD, BCOP, has no relevant conflicts of interest to report.

Lipika Goyal, MD, MPhil

Associate Professor in Medicine
Director of Gastrointestinal Oncology
Stanford School of Medicine
Palo Alto, California

Lipika Goyal, MD, has disclosed that she has received consulting fees from Alentis Therapeutics, Black Diamond, Genentech, H3 Biomedicine, Incyte, Mefial, QED, Servier, Sirtex, and Taiho Oncology; has received funds for research from Adaptimmune, Bayer, Eisai, Merck, Macrogenics, Genentech, Novartis, Incyte, Eli Lilly, Loxo Oncology, Relay Therapeutis, QED, Servier, Taiho Oncology Ltd , Leap Therapeutics, Bristol Meyers Squibb, Nucana; and has served on a DSMC for AstraZeneca.

Caroline Kuhlman, NP

Nurse Practitioner
GI Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Caroline Kuhlman, NP, has no relevant conflicts of interest to report.

Staff Disclosure

Staff

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer had individual publicly traded stocks/stock options in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-137-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 13, 2022, through May 12, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this program is to improve the knowledge and competence of learners to incorporate newer patient-centered therapies into the management of patients with CCA.